Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

276.47 +4.05 (+1.49%)

Official Closing Price Updated: 7:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens ↗

Today 10:50 EDT

These companies might bend during a downturn, but they won’t break.

Via The Motley Fool

Topics Economy Intellectual Property

2 Cash-Producing Stocks on Our Watchlist and 1 We Avoid

Today 0:38 EDT

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

Topics Energy

5 Stocks to Buy That Have Raised Their Dividends Every Year Since 2000 ↗

October 07, 2026

Each of these stocks, representing a different sector, is on an impressive run of dividend growth.

Via The Motley Fool

Topics Artificial Intelligence

Wednesday's session: top gainers and losers in the S&P500 index ↗

October 07, 2026

Via Chartmill

Malissa LaRoche of True Beauty Aesthetics Advances MD Codes Facial Injection Training

October 06, 2026

MOUNT PLEASANT, SC - October 06, 2026 - Malissa LaRoche, PA-C, owner and injector at True Beauty Aesthetics, has continued her education in MD Codes, the facial assessment and injection...

Via Press Advantage

Topics Economy

3 of the Best Growth Stocks to Buy in October 2026 ↗

October 06, 2026

These stocks have tremendous businesses, and their valuations are incredibly low.

Via The Motley Fool

Topics Artificial Intelligence

HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English. ↗

October 06, 2026

A recent analyst lays out a concrete bull case, but it is not the only path to higher prices for AbbVie.

Via The Motley Fool

Should You Buy AbbVie Stock Before Oct. 30? ↗

October 06, 2026

The healthcare company will release its third-quarter numbers later this month.

Via The Motley Fool

Why I Think These Are the 2 Smartest Stocks to Buy With $5,000 in October ↗

October 05, 2026

AbbVie and Medtronic are both stable blue chip dividend plays in this choppy market.

Via The Motley Fool

Topics Bonds Economy Intellectual Property

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

October 05, 2026

From Genmab A/S

Via Business Wire

3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note ↗

October 03, 2026

With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.

Via MarketBeat

Topics Bonds Retirement

AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think. ↗

October 03, 2026

Another potential blockbuster just joined AbbVie's drug portfolio.

Via The Motley Fool

Topics Intellectual Property

3 of the Best ETFs to Buy and Hold if a Recession Is Coming ↗

October 02, 2026

VHT, BND, and VOO could be your best bets in the next economic downturn.

Via The Motley Fool

Topics ETFs Economy Regulatory Compliance

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 01, 2026

AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.

Via The Motley Fool

Topics Economy

AbbVie Stock: Buy, Sell, or Hold in October? ↗

September 30, 2026

The pharmaceutical giant still looks like a stable long-term investment.

Via The Motley Fool

Topics Intellectual Property

3 Healthcare Dividend Stocks Offering More Than Just Income ↗

September 30, 2026

AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.

Via MarketBeat

1 Profitable Stock to Keep an Eye On and 2 Facing Challenges

September 30, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

Topics Supply Chain

Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks. ↗

September 27, 2026

Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.

Via The Motley Fool

Topics Bonds Economy

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 25, 2026

AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? ↗

September 25, 2026

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026? ↗

September 24, 2026

Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? ↗

September 24, 2026

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.

Via The Motley Fool

Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade ↗

September 24, 2026

It would be hard for investors to replicate the company's return over the past decade.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September? ↗

September 22, 2026

These companies are committed to rewarding shareholders.

Via The Motley Fool

Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)

September 21, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe...

Via StockStory

Topics Artificial Intelligence

AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now? ↗

September 19, 2026

AbbVie's market-beating days don't seem to be over yet.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 18, 2026

AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.

Via The Motley Fool

Topics Intellectual Property

Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded? ↗

September 16, 2026

The company is still looking to bounce back after the beating it took in recent years.

Via The Motley Fool

Topics Economy

Is AbbVie the Best Dividend King to Buy in September? ↗

September 16, 2026

It is certainly a good Dividend King to buy in September.

Via The Motley Fool

Topics Intellectual Property

3 Dividend Stocks That Are No-Brainer Buys Right Now, Starting With This Healthcare Giant ↗

September 15, 2026

These three stocks meet multiple criteria for long-term dividend investing success.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.